Canadian health news — a first for one of the cruelest rare conditions in medicine. Rhythm Pharmaceuticals announced September 22 that Health Canada has approved IMCIVREE (setmelanotide) for weight management in adult and pediatric patients aged 4 and older living with acquired hypothalamic obesity. It is the first targeted therapy ever approved in Canada for the condition — and for the families living with it, the word “targeted” carries the weight.
By Maplestime News Desk | Winnipeg, Manitoba | September 24, 2026
Sources: Rhythm Pharmaceuticals | GlobeNewswire | Last updated: September 24, 2026
Key Takeaways
- Health Canada approved IMCIVREE (setmelanotide) for weight management in patients 4 years and older with acquired hypothalamic obesity (HO).
- It is the first targeted therapy approved in Canada for acquired HO — a rare, complex MC4R pathway disease.
- Acquired HO develops after injury to the hypothalamus, often following treatment for a brain tumour, and causes accelerated, sustained weight gain, extreme hunger (hyperphagia) and major impacts on quality of life.
- IMCIVREE was first approved by Health Canada in 2023 for obesity due to Bardet-Biedl syndrome and certain rare genetic deficiencies (POMC, PCSK1, LEPR).
- Jennifer Lee, Rhythm’s EVP and Head of North America: “The approval of this additional indication for IMCIVREE provides healthcare professionals with an important new treatment option for eligible patients in Canada.”
A condition that starts with surviving something else
Acquired hypothalamic obesity does not arrive on its own. It follows an injury to the hypothalamus — the brain’s control centre for hunger, energy and hormones — most often after treatment for a brain tumour in childhood. The child survives the tumour. Then the weight gain starts: rapid, relentless, driven by a broken satiety signal and an insatiable hunger that no amount of willpower touches. Diet and exercise, the standard prescription, barely dent it, because the underlying machinery is damaged.
Setmelanotide works downstream of the damage, activating the MC4R pathway that regulates hunger and energy expenditure. It does not repair the hypothalamus — but it gives the body’s appetite signalling a way back online.
From ultra-rare to merely rare
IMCIVREE’s first Canadian approval, in 2023, covered vanishingly rare genetic obesities — Bardet-Biedl syndrome and deficiencies in the POMC, PCSK1 and LEPR genes. Acquired HO is a larger, if still small, population: children and adults whose obesity began with a brain injury, many of them childhood cancer survivors. For them, there has never been a therapy designed for their disease. Now there is one.
“The approval of this additional indication for IMCIVREE provides healthcare professionals with an important new treatment option for eligible patients in Canada,” said Jennifer Lee, Rhythm’s Executive Vice President and Head of North America. The company says it is grateful to the Canadian patient and healthcare community and looks forward to making the therapy available to patients living with acquired HO.
Availability and reimbursement are the next hurdles — approval is the starting gun, not the finish line. But for families who have watched a child survive cancer only to face a second, invisible battle with their own body, a first targeted therapy is not a small thing. It is the first time medicine has spoken their language.
Enjoying Maplestime? Support independent Canadian journalism — no paywall, no corporate owners.
